Focused On-demand Library for Anaphase-promoting complex subunit 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UJX6

UPID:

ANC2_HUMAN

Alternative names:

Cyclosome subunit 2

Alternative UPACC:

Q9UJX6; Q5VSG1; Q96DG5; Q96GG4; Q9P2E1

Background:

Anaphase-promoting complex subunit 2, also known as Cyclosome subunit 2, plays a pivotal role in cell cycle regulation. It forms a part of the anaphase promoting complex/cyclosome (APC/C), a crucial E3 ubiquitin ligase that governs mitosis and G1 phase progression. This complex is instrumental in ubiquitination and degradation of target proteins, favoring 'Lys-11'-linked polyubiquitin chains formation, while also facilitating 'Lys-48'- and 'Lys-63'-linked chains to a lesser extent. It is key in synaptic vesicle clustering at the presynaptic membrane in neurons, driving presynaptic differentiation through NEUROD2 degradation.

Therapeutic significance:

Understanding the role of Anaphase-promoting complex subunit 2 could open doors to potential therapeutic strategies.